Sangamo Therapeutics, Inc.

NASDAQ:SGMO

Biotechnology

Healthcare
$0.18 +2.06%

+$0.00 today

Market cap
$70.43M
Beta
1.29
P/E (TTM)
-0.5
EPS (TTM)
-$0.32
52W Low $0.10High $0.77

Volume 0.61M

Average 9.53M

SGMO Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

Sangamo Therapeutics, Inc.NASDAQ: SGMO

Gross Profit · Q1 FY2026 · quarter ended Mar 2026

Gross profit declines year over year

Q1 FY2026 gross profit of $1.44M fell 77.6% year over year, behind the -45.8% change in trailing-twelve-month gross profit. Sequentially, it fell 89.9% from the prior quarter. Over 3 fiscal years it compounded at -31.5% a year.

Context

  • Gross profit amounted to 80.8% of revenue in FY2025, down 19.2 pp from a year earlier.
  • Gross profit increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -77.6% toward the trailing-twelve-month pace of -45.8%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$1.44M-89.9% QoQ
Last fiscal yearDec 2025
$31.95M-44.7% YoY
LTMMar 2026
$34.56M-45.8% YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-77.6%——
1 year-44.7%——
3-year CAGR-31.5%——
5-year CAGR——
10-year CAGR——

Gross Profit history

USD · from the income statement

Latest · FY2025
31.95M USD
Year-over-year change
-44.7%
4-year CAGR
-26.7%

Gross Profit vs competitors

How SGMO compares with its peers on the latest reported figures

  • Peers report in different currencies, so gross profit is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -45.8% is the 7th highest of 10, against a peer median of -2.5%.
  • Gross profit amounts to 100.0% of revenue for SGMO, versus a peer median of 92.0%.
SGMO Competitors
Gross Profit for SGMO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CDXSCodexis, Inc.LTM Mar 2026$65.55M USD+83.9%-15.3%83.9%
IVVDInvivyd, Inc.LTM Mar 2026$51.41M USD+50.2%—92.0%
SGMOSangamo Therapeutics, Inc.LTM Mar 2026$34.56M USD-45.8%-31.5%100.0%
CCCCC4 Therapeutics, Inc.LTM Mar 2026$33.06M USD-2.5%-3.5%94.8%
OABIOmniAb, Inc.LTM Mar 2026$10.25M USD-61.7%—35.5%
RANIRani Therapeutics Holdings, Inc.LTM Mar 2026$3.01M USD+150.7%—94.9%
IPHAInnate Pharma S.A.FY2025€2.79M EUR-77.9%-22.6%100.0%
ARMPArmata Pharmaceuticals, Inc.LTM Mar 2026$2.14M USD-35.6%—72.2%
MISTMilestone Pharmaceuticals Inc.LTM Mar 2026$1.69M USD—-34.1%94.7%
IMDXInsight Molecular Diagnostics Inc.LTM Mar 2026$379.5K USD-81.2%—19.5%
MOLNMolecular Partners AGLTM Mar 2026-CHF 2.61M CHF+91.8%——
Peer median (excluding SGMO) —-2.5%-19.0%92.0%

Competitors are the stored peer set for SGMO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue110.7M111.3M176.23M57.8M39.55M
Cost of Revenue012.11M007.6M
Gross Profit110.7M99.19M176.23M57.8M31.95M
Gross Margin100.0%89.1%100.0%100.0%80.8%
Research & Development230.82M249.9M234.06M111.52M112.67M
Selling, General & Admin63.22M62.68M61.17M44.73M34.89M
Operating Expenses294.04M300.47M450.24M161.77M139.95M
Depreciation & Amortization17.64M12.11M22.19M9.36M7.6M
EBITDA(160.35M)(179.74M)(96.8M)(89.09M)(115.9M)
EBITDA Margin-144.9%-161.5%-54.9%-154.1%-293.0%
Operating Income(183.34M)(201.28M)(274.01M)(103.97M)(108M)
Operating Margin-165.6%-180.8%-155.5%-179.9%-273.1%
Interest Income5.35M9.43M11.1M5.86M1.3M
Interest Expense00000
Other Income / Expenses5.35M9.43M11.1M5.86M(15.5M)
Income Before Tax(177.99M)(191.85M)(262.9M)(98.11M)(123.5M)
Pre-Tax Margin-160.8%-172.4%-149.2%-169.7%-312.2%
Income Tax Expense306K429K(5.07M)(167K)(568K)
Net Income(178.29M)(192.28M)(257.83M)(97.94M)(122.93M)
Net Margin-161.1%-172.8%-146.3%-169.4%-310.8%
EPS (Basic)(1.23)(1.25)(1.48)(0.49)(0.44)
EPS (Diluted)(1.23)(1.25)(1.48)(0.49)(0.44)
Weighted Avg Shares144.57M154.35M174.44M201.7M280.19M
Weighted Avg Shares (Diluted)144.57M154.35M174.44M201.7M280.19M

Sangamo Therapeutics, Inc.

NASDAQ:SGMO

Intrinsic Alpha fair value

Locked

Current Price

$0.18

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.